GRFS
Price
$7.55
Change
-$0.50 (-6.21%)
Updated
Dec 18, 04:17 PM (EDT)
71 days until earnings call
PFE
Price
$25.89
Change
-$0.54 (-2.04%)
Updated
Dec 18, 04:59 PM (EDT)
48 days until earnings call
Ad is loading...

GRFS vs PFE

Header iconGRFS vs PFE Comparison
Open Charts GRFS vs PFEBanner chart's image
Grifols SA
Price$7.55
Change-$0.50 (-6.21%)
Volume$200
CapitalizationN/A
Pfizer
Price$25.89
Change-$0.54 (-2.04%)
Volume$331.57K
CapitalizationN/A
GRFS vs PFE Comparison Chart
Loading...
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GRFS vs. PFE commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GRFS is a Buy and PFE is a StrongBuy.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (GRFS: $8.05 vs. PFE: $26.43)
Brand notoriety: GRFS: Not notable vs. PFE: Notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GRFS: 114% vs. PFE: 165%
Market capitalization -- GRFS: $5.48B vs. PFE: $157.14B
GRFS [@Pharmaceuticals: Major] is valued at $5.48B. PFE’s [@Pharmaceuticals: Major] market capitalization is $157.14B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GRFS’s FA Score shows that 1 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s).

  • GRFS’s FA Score: 1 green, 4 red.
  • PFE’s FA Score: 1 green, 4 red.
According to our system of comparison, both GRFS and PFE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GRFS’s TA Score shows that 5 TA indicator(s) are bullish while PFE’s TA Score has 5 bullish TA indicator(s).

  • GRFS’s TA Score: 5 bullish, 5 bearish.
  • PFE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, PFE is a better buy in the short-term than GRFS.

Price Growth

GRFS (@Pharmaceuticals: Major) experienced а +11.81% price change this week, while PFE (@Pharmaceuticals: Major) price change was +3.36% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.43%. For the same industry, the average monthly price growth was -3.05%, and the average quarterly price growth was -1.91%.

Reported Earning Dates

GRFS is expected to report earnings on Feb 27, 2025.

PFE is expected to report earnings on Feb 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-2.43% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PFE($157B) has a higher market cap than GRFS($5.48B). PFE has higher P/E ratio than GRFS: PFE (74.92) vs GRFS (68.68). PFE YTD gains are higher at: -2.586 vs. GRFS (-30.363). PFE has higher annual earnings (EBITDA): 9.56B vs. GRFS (640M). PFE has more cash in the bank: 12.7B vs. GRFS (544M). GRFS has less debt than PFE: GRFS (11.1B) vs PFE (70.8B). PFE has higher revenues than GRFS: PFE (58.5B) vs GRFS (6.54B).
GRFSPFEGRFS / PFE
Capitalization5.48B157B3%
EBITDA640M9.56B7%
Gain YTD-30.363-2.5861,174%
P/E Ratio68.6874.9292%
Revenue6.54B58.5B11%
Total Cash544M12.7B4%
Total Debt11.1B70.8B16%
FUNDAMENTALS RATINGS
GRFS vs PFE: Fundamental Ratings
GRFS
PFE
OUTLOOK RATING
1..100
511
VALUATION
overvalued / fair valued / undervalued
1..100
8
Undervalued
4
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8683
PRICE GROWTH RATING
1..100
6459
P/E GROWTH RATING
1..100
10096
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PFE's Valuation (4) in the Pharmaceuticals Major industry is in the same range as GRFS (8). This means that PFE’s stock grew similarly to GRFS’s over the last 12 months.

PFE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as GRFS (100). This means that PFE’s stock grew similarly to GRFS’s over the last 12 months.

PFE's SMR Rating (83) in the Pharmaceuticals Major industry is in the same range as GRFS (86). This means that PFE’s stock grew similarly to GRFS’s over the last 12 months.

PFE's Price Growth Rating (59) in the Pharmaceuticals Major industry is in the same range as GRFS (64). This means that PFE’s stock grew similarly to GRFS’s over the last 12 months.

PFE's P/E Growth Rating (96) in the Pharmaceuticals Major industry is in the same range as GRFS (100). This means that PFE’s stock grew similarly to GRFS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GRFSPFE
RSI
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
63%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
55%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
51%
MACD
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
61%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
57%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
73%
Bullish Trend 2 days ago
50%
Advances
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 6 days ago
58%
Declines
ODDS (%)
Bearish Trend 6 days ago
75%
Bearish Trend 8 days ago
63%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
66%
Bearish Trend 2 days ago
57%
Aroon
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
53%
View a ticker or compare two or three
Ad is loading...
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ARCM100.50N/A
N/A
Arrow Reserve Capital Management ETF
XMAR36.21-0.01
-0.03%
FT Vest U.S. Eq Enh & ModBufETF-Mar
PZA23.82-0.12
-0.50%
Invesco National AMT-Free Muni Bd ETF
LITP6.98-0.10
-1.41%
Sprott Lithium Miners ETF
URTY57.36-2.07
-3.48%
ProShares UltraPro Russell2000

GRFS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GRFS has been closely correlated with GIKLY. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if GRFS jumps, then GIKLY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRFS
1D Price
Change %
GRFS100%
+5.64%
GIKLY - GRFS
68%
Closely correlated
+2.19%
GIFOF - GRFS
37%
Loosely correlated
N/A
PFE - GRFS
28%
Poorly correlated
+4.67%
GIFLF - GRFS
23%
Poorly correlated
N/A
AMGN - GRFS
21%
Poorly correlated
-0.21%
More